Conclusions

• FDA's exposure estimates will be used to establish priorities

  • Risk assessment will inform risk management decisions
  • Public health considerations'
  • Future research

• Modeling process will allow evaluation of "what-if?" scenarios for mitigation measures

• Additional data will be incorporated into future exposure assessments and scenarios as they become available